Minimal Residual Disease in Peripheral T-cell Lymphoma

Inclusion Criteria:

- At least 18 years of age.

- Histologically-confirmed peripheral T-cell lymphoma being treated with curative
intent. Eligible histologies include: peripheral T-cell lymphoma, not otherwise
specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphoma, ALK
negative; and anaplastic large cell lymphoma, ALK positive.

- Plan for treatment with frontline multi-agent anthracycline containing chemotherapy
for curative intent (for example, CHOP, CHOEP, EPOCH). A frontline therapy program can
include different sequential phases of treatment, including high-dose therapy and
autologous stem cell transplantation.

- Availability of pre-treatment test specimen from bone marrow, blood, lymph node, or
alternate site to identify tumor-specific clonotype, or willingness to undergo biopsy
if sufficient tissue is not available at time of enrollment (e.g. 15 slides from fixed
formalin-fixed paraffin embedded tumor tissue

*Patients who have less than 15 slides of fixed formalin-fixed paraffin embedded tumor
tissue may be considered for enrollment after discussion with the study principal
investigator

- Able to understand and willing to sign an IRB approved written informed consent
document.

Exclusion Criteria:

- Receiving second line of therapy or greater.

- Diagnosis of primary cutaneous T-cell lymphoma, extranodal NK-cell lymphoma, acute
T-cell lymphoma/leukemia, hepatosplenic T-cell lymphoma.